Psychiatry Medical News about risperidone panic attacks

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Omega-3 fatty acids for bipolar disorder

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized single-blind study.
BMC Psychiatry, 06/01/09

Prosser JM et al. - This study can identify no difference in the efficacy of paroxetine and low-dose risperidone in the treatment of panic attacks. Low-dose risperidone appears to be tolerated equally well as paroxetine. Low-dose risperidone may be an effective treatment for anxiety disorders in which panic attacks are a significant component.

Methods

Fifty six subjects with a history of panic attacks were randomized to receive either risperidone or paroxetine.
The subjects were then followed for eight weeks.
Outcome measures included the Panic Disorder Severity Scale (PDSS), the Hamilton Anxiety Scale (Ham-A), the Hamilton Depression Rating Scale (Ham-D), the Sheehan Panic Anxiety Scale-Patient (SPAS-P), and the Clinical Global Impression scale (CGI).

Results

All subjects demonstrated a reduction in both the frequency and severity of panic attacks regardless of treatment received.
Statistically significant improvements in rating scale scores for both groups were identified for the PDSS, the Ham-A, the Ham-D, and the CGI.
There was no difference between treatment groups in the improvement in scores on the measures PDSS, Ham-A, Ham-D, and CGI.
Post hoc tests suggest that subjects receiving risperidone may have a quicker clinical response than subjects receiving paroxetine.

<< Previous
Decision makers experiences of prioritisation and views about how...

Next >>
A Double-Blind Trial of Gabapentin Versus Lorazepam in the...